Nurix Therapeutics (NRIX) Update / Briefing June 12, 2025 08:00 AM ET Speaker0 Welcome to the New York's Therapeutics twenty twenty five investor call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session. I would now like to turn the conference over to Newark's President and CEO, Arthur Sands. Arthur, you may begin. Speaker1 Thanks, Paul. Welcome to our call and our presentation today entitled meeting the needs of patients with CLL and Waldenstrom's ...

Nurix Therapeutics (NRIX) 2025 Conference June 04, 2025 03:45 PM ET Speaker0 Rutideg, which we call bexdeg for short, being a degrader. We've got an important new suffix on there to indicate it's a degrader. So, I'll be calling it bexdeg n x five nine four eight. Speaker1 Okay. Bexdeg. Speaker0 Yeah, bexdeg. Speaker1 Yeah, awesome. So, maybe just to clarify, this EHA update will be focused on the phase 1a, more mature data, but not from the phase 1b expansion cohort for CLL. Speaker0 Right. It'll be on the ...